In SCC131 oral cancer cells, gedunin alone and in combination with epalrestat prevented cancer hallmarks presumably by inhibiting AR-mediated ROS signaling and co-inactivation of Akt, Erk, and IKK/NF-κB signaling, with the combination being more effective than the single agents. Here, AR is linked to cancer.